BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eychenne R, Chérel M, Haddad F, Guérard F, Gestin JF. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight". Pharmaceutics 2021;13:906. [PMID: 34207408 DOI: 10.3390/pharmaceutics13060906] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Brown MA. Separation of radium and actinium using zirconia. Applied Radiation and Isotopes 2022;185:110238. [DOI: 10.1016/j.apradiso.2022.110238] [Reference Citation Analysis]
2 Li F, Yang Y, Liao J, Liu N. Recent progress of astatine-211 in endoradiotherapy: Great advances from fundamental properties to targeted radiopharmaceuticals. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.025] [Reference Citation Analysis]
3 Hanaoka H, Ohshima Y, Suzuki H, Sasaki I, Watabe T, Ooe K, Watanabe S, Ishioka NS. Enhancing the Therapeutic Effect of 2-211At-astato-α-methyl-L-phenylalanine with Probenecid Loading. Cancers (Basel) 2021;13:5514. [PMID: 34771676 DOI: 10.3390/cancers13215514] [Reference Citation Analysis]
4 Daly SR, Bellott BJ, McAlister DR, Horwitz EP, Girolami GS. Pr(H3BNMe2BH3)3 and Pr(thd)3 as Volatile Carriers for Actinium-225. Deposition of Actinium-Doped Praseodymium Boride Thin Films for Potential Use in Brachytherapy. Inorg Chem 2022. [PMID: 35510902 DOI: 10.1021/acs.inorgchem.2c00442] [Reference Citation Analysis]
5 Walter RB. Where do we stand with radioimmunotherapy for acute myeloid leukemia? Expert Opin Biol Ther 2022;:1-7. [PMID: 35350938 DOI: 10.1080/14712598.2022.2060735] [Reference Citation Analysis]
6 Kafle A, Armentrout PB. Experimental and computational investigation of the bond energy of thorium dicarbonyl cation and theoretical elucidation of its isomerization mechanism to the thermodynamically most stable isomer, thorium oxide ketenylidene cation, OTh+CCO. Phys Chem Chem Phys 2022;24:842-53. [PMID: 34908066 DOI: 10.1039/d1cp04263g] [Reference Citation Analysis]
7 Wharton L, Zhang C, Yang H, Zeisler J, Radchenko V, Rodríguez-Rodríguez C, Osooly M, Patrick BO, Lin KS, Bénard F, Schaffer P, Orvig C. [213Bi]Bi3+/[111In]In3+-neunpa-cycMSH: Theranostic Radiopharmaceutical Targeting Melanoma─Structural, Radiochemical, and Biological Evaluation. Bioconjug Chem 2022. [PMID: 35239331 DOI: 10.1021/acs.bioconjchem.2c00038] [Reference Citation Analysis]
8 Yoshimoto M, Yoshii Y, Matsumoto H, Shinada M, Takahashi M, Igarashi C, Hihara F, Tachibana T, Doi A, Higashi T, Fujii H, Washiyama K. Evaluation of Aminopolycarboxylate Chelators for Whole-Body Clearance of Free 225Ac: A Feasibility Study to Reduce Unexpected Radiation Exposure during Targeted Alpha Therapy. Pharmaceutics 2021;13:1706. [PMID: 34683999 DOI: 10.3390/pharmaceutics13101706] [Reference Citation Analysis]
9 Neels OC, Kopka K, Liolios C, Afshar-Oromieh A. Radiolabeled PSMA Inhibitors. Cancers (Basel) 2021;13:6255. [PMID: 34944875 DOI: 10.3390/cancers13246255] [Reference Citation Analysis]
10 Zhou X, Dong L, Shen L. Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals. Molecules 2021;26:6997. [PMID: 34834087 DOI: 10.3390/molecules26226997] [Reference Citation Analysis]
11 Del Olmo-Garcia MI, Prado-Wohlwend S, Andres A, Soriano JM, Bello P, Merino-Torres JF. Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms. Biomedicines 2021;9:1810. [PMID: 34944626 DOI: 10.3390/biomedicines9121810] [Reference Citation Analysis]
12 Hu A, Brown V, MacMillan SN, Radchenko V, Yang H, Wharton L, Ramogida CF, Wilson JJ. Chelating the Alpha Therapy Radionuclides 225Ac3+ and 213Bi3+ with 18-Membered Macrocyclic Ligands Macrodipa and Py-Macrodipa. Inorg Chem 2021. [PMID: 34965102 DOI: 10.1021/acs.inorgchem.1c03670] [Reference Citation Analysis]